

## Zelluna lists on Euronext

- **Market capitalisation of approximately NOK 463 million**
- **Private placement raising NOK 51.7 million**
- **A result of the business combination of Ultimovacs and Zelluna Immunotherapy**




**Oslo – 4 March 2025** – The biopharmaceutical company Zelluna (ticker: ZLNA) was today admitted to trading on Euronext Oslo Børs following the business combination between Ultimovacs ASA and Zelluna Immunotherapy AS, announced in December 2024.

Zelluna is a biopharmaceutical company with a mission to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The company is based in Oslo, Norway.

In connection to the business combination of the two companies, a private placement was completed raising NOK 51.7 million at a price of NOK 2.60 per stock in December. The issue price of Zelluna shares was set at NOK 2.29 per share at market opening, and market capitalisation was NOK 463.2 million on the day of listing.

**Namir Hassan, CEO of Zelluna ASA, said:** *"Today marks a pivotal moment as Zelluna joins Euronext Oslo Børs, as the first ever cell therapy company to be traded on it. Through the unwavering dedication of our team, board and investors, we have pioneered an "off the shelf" cell therapy platform from basic research to the world's first lead asset heading towards the clinic. Listing on Euronext Oslo Børs opens new doors for growth and innovation, enhances our visibility and provides the financial flexibility needed to accelerate the development of our groundbreaking cell therapies, getting them closer to solid cancer patients who need them."*



**Caption:** Namir Hassan, CEO of Zelluna, and Anders Tuv, Chair of the Board, rang the bell during a ceremony this morning to celebrate Zelluna's first day of trading. The company was welcomed by Øivind Amundsen, CEO of Euronext Oslo Børs. (Photo: Thomas Brun | NTB).

## CONTACTS

**CONTACT EURONEXT - [mediateam@euronext.com](mailto:mediateam@euronext.com)**

Norway

Cathrine Lorvik Segerlund

+47 41 69 59 10

### About Zelluna ASA

Zelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale.

The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used "off the shelf" to overcome scaling limitations of current cell therapies. The lead programme is the world's first MAGE-A4 targeting "off the shelf" TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follow.

The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through to clinical development of TCR and cell-based therapies including marketed products.

### About Euronext

Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe's leading electronic fixed

income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway and Portugal.

As of December 2024, Euronext's regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal host over 1,800 listed issuers with around €6 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices.

For the latest news, go to [euronext.com](https://www.euronext.com) or follow us on [X](#) and [LinkedIn](#).

#### Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at [www.euronext.com/terms-use](https://www.euronext.com/terms-use).

© 2025, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: [www.euronext.com/privacy-policy](https://www.euronext.com/privacy-policy). In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: [www.euronext.com/data-subjects-rights-request-information](https://www.euronext.com/data-subjects-rights-request-information). To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at [connect2.euronext.com/form/data-subjects-rights-request](https://connect2.euronext.com/form/data-subjects-rights-request) or email our Data Protection Officer at [dpo@euronext.com](mailto:dpo@euronext.com).